Global Generic Drugs Market Research Report Information by Type, by Brand, by Indication, by Route of Administration, by Distribution Channel, and by Region

Description

List of Tables

Global Generic Drugs Market Research Report Information by Type (Simple Generics and Super Generics), by Brand (Pure Generic and Branded Generic), by Indication (Central Nervous System (CNS), Cardiovascular, Urology, Oncology, Respiratory, and Others), by Route of Administration (Oral, Topical, Parenteral, and Others), by Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy), and by Region (North America, Europe, Asia-Pacific, and Rest of the World - Forecast till 2032

Market Overview

In 2023, the generic drugs market was valued at USD 410.60 billion. The Generic Drugs Market is expected to increase from USD 437.90 billion in 2024 to USD 874.36 billion by 2032, with a compound annual growth rate (CAGR) of 7.85% over the forecast period (2024-2032). The worldwide generic medicine industry is being driven by rising prevalence of chronic diseases around the world, as well as increased strategic activities by market players. However, voluntary product recalls by industry participants are projected to impede global market growth. Nonetheless, investment in research and development (R&D) for generic pharmaceuticals is expected to generate attractive market prospects.

The rising prevalence of chronic diseases around the world is a primary driver of the global generic medication market's growth. With ailments including cancer, neurology, cardiovascular diseases, inflammatory diseases, and others on the rise, there is an increased desire for low-cost treatment choices, prompting patients and healthcare providers to turn to generic pharmaceuticals.

Market Segment insights

The Generic Drugs Market is segmented by kind, with simple generics and super generics.

The Generic Drugs Market is segmented by brand into pure generic and branded generic.

The Generic Drugs Market is segmented by indication, including central nervous system (CNS), cardiovascular, urology, cancer, respiratory, and others.

Regional insights

The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. The North American Generic Drugs market is expanding rapidly, driven by reasons such as increased demand for Generic Drugs in hospitals and medical settings, technological improvements, and the rising prevalence of chronic conditions.

The Europe Generic Drugs market accounted for the second-largest market share due to well-established healthcare infrastructure, which is driven by collaborations and partnerships between industry players, research organizations, and healthcare providers. Furthermore, Germany Generic Drugs providers are said to have the greatest market share, while France Generic Drugs providers are expected to be the fastest rising market in Europe.

The Asia-Pacific Generic Drugs market is predicted to expand the fastest from 2023 to 2032, owing to the prevalence of chronic medical problems such as cancer, diabetes, and cardiovascular disease, as well as increased healthcare spending and investments in R&D. Furthermore, China Generic Drugs accounted for the greatest market share, while India Generic Drugs is expected to be the fastest expanding market in the Asia Pacific region.

Major Players

Sun Pharmaceutical Industries Ltd. (India), Lupin Pharmaceuticals, Inc. (India), Endo International plc (Ireland), Aurobindo Pharma (India), Aspen Holdings (South Africa), Teva Pharmaceuticals Industries Ltd. (Israel), Viatris Inc. (US), Cipla ltd. (India), Fresenius SE & Co. KGaA (Germany), and Novartis AG (Switzerland) are among the key companies in the Generic Drugs market.

Product Code: MRFR/Pharma/10830-HCR

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION
2.2 SCOPE OF THE STUDY
2.3 RESEARCH OBJECTIVE
2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW
3.2 DATA FLOW
- 3.2.1 DATA MINING PROCESS
3.3 PURCHASED DATABASE:
3.4 SECONDARY SOURCES:
- 3.4.1 SECONDARY RESEARCH DATA FLOW:
3.5 PRIMARY RESEARCH:
- 3.5.1 PRIMARY RESEARCH DATA FLOW:
- 3.5.2 PRIMARY RESEARCH: NUMBER OF INTERVIEWS CONDUCTED
- 3.5.3 PRIMARY RESEARCH: REGIONAL COVERAGE
3.6 APPROACHES FOR MARKET SIZE ESTIMATION:
- 3.6.1 REVENUE ANALYSIS APPROACH
3.7 DATA FORECASTING
- 3.7.1 DATA FORECASTING TYPE
3.8 DATA MODELING
- 3.8.1 MICROECONOMIC FACTOR ANALYSIS:
- 3.8.2 DATA MODELING:
3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION
4.2 DRIVERS
- 4.2.1 INCREASING INCIDENCES OF CHRONIC DISEASES ACROSS THE GLOBE
- 4.2.2 RISING STRATEGIC INITIATIVES BY MARKET PLAYERS
4.3 RESTRAINTS
- 4.3.1 VOLUNTARY PRODUCT RECALLS FROM MARKET PLAYERS
4.4 OPPORTUNITY
- 4.4.1 INVESMTENT ON RESEARCH & DEVELOPMENT (R&D) FOR GENERIC MEDICINE

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL
- 5.1.1 THREAT OF NEW ENTRANTS
- 5.1.2 BARGAINING POWER OF SUPPLIERS
- 5.1.3 THREAT OF SUBSTITUTES
- 5.1.4 BARGAINING POWER OF BUYERS
- 5.1.5 INTENSITY OF RIVALRY
5.2 IMPACT OF COVID-19 ON THE GLOBAL GENERIC DRUGS MARKET
5.3 TRENDS IN DEVELOPMENTS OF INDIVIDUAL MARKETS (EU, USA, INDIA, CHINA, OTHER)
5.4 TRENDS IN THE DEVELOPMENT OF THERAPEUTIC AREAS
5.5 TRENDS IN MANUFACTURING SITES
5.6 TRENDS IN NEW TECHNOLOGICAL PLATFORMS FOR DRUGS
5.7 TRENDS IN IP
5.8 TRENDS IN QUALITY REQUIREMENTS
5.9 TRENDS IN REGULATORY REQUIREMENTS

6 GLOBAL GENERIC DRUGS MARKET, BY TYPE

6.1 OVERVIEW
6.2 SIMPLE GENERICS
6.3 SUPER GENERICS

7 GLOBAL GENERIC DRUGS MARKET, BY BRAND

7.1 OVERVIEW
7.2 PURE GENERIC
7.3 BRANDED GENERIC

8 GLOBAL GENERIC DRUGS MARKET, BY INDICATION

8.1 OVERVIEW
8.2 CENTRAL NERVOUS SYSTEM (CNS)
8.3 CARDIOVASCULAR
8.4 UROLOGY
8.5 ONCOLOGY
8.6 RESPIRATORY
8.7 OTHERS

9 GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION

9.1 OVERVIEW
9.2 ORAL
9.3 TOPICAL
9.4 PARENTERAL
9.5 OTHERS

10 GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL

10.1 OVERVIEW
10.2 HOSPITAL PHARMACY
10.3 RETAIL PHARMACY
10.4 ONLINE PHARMACY

11 GLOBAL GENERIC DRUGS MARKET, BY REGION

11.1 OVERVIEW
11.2 NORTH AMERICA
- 11.2.1 US
- 11.2.2 CANADA
11.3 EUROPE
- 11.3.1 GERMANY
- 11.3.2 FRANCE
- 11.3.3 UK
- 11.3.4 ITALY
- 11.3.5 SPAIN
- 11.3.6 REST OF EUROPE
11.4 ASIA-PACIFIC
- 11.4.1 CHINA
- 11.4.2 INDIA
- 11.4.3 JAPAN
- 11.4.4 SOUTH KOREA
- 11.4.5 AUSTRALIA
- 11.4.6 REST OF ASIA-PACIFIC
11.5 REST OF THE WORLD
- 11.5.1 MIDDLE EAST & AFRICA
- 11.5.2 LATIN AMERICA

12 COMPETITIVE LANDSCAPE

12.1 INTRODUCTION
12.2 MARKET SHARE ANALYSIS,
12.3 COMPETITOR DASHBOARD
12.4 PUBLIC PLAYERS STOCK SUMMARY
12.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANICAL
12.6 KEY DEVELOPMENTS & GROWTH STRATEGIES
- 12.6.1 PRODUCT LAUNCH / PRODUCT APPROVAL
- 12.6.2 EXPANSION

13 COMPANY PROFILES

13.1 SUN PHARMACEUTICAL INDUSTRIES LTD.
- 13.1.1 COMPANY OVERVIEW
- 13.1.2 FINANCIAL OVERVIEW
- 13.1.3 PRODUCTS OFFERED
- 13.1.4 KEY DEVELOPMENTS
- 13.1.5 SWOT ANALYSIS
- 13.1.6 KEY STRATEGIES
13.2 LUPIN PHARMACEUTICALS, INC.
- 13.2.1 COMPANY OVERVIEW
- 13.2.2 FINANCIAL OVERVIEW
- 13.2.3 PRODUCTS OFFERED
- 13.2.4 KEY DEVELOPMENTS
- 13.2.5 SWOT ANALYSIS
- 13.2.6 KEY STRATEGIES
13.3 ENDO INTERNATIONAL PLC
- 13.3.1 COMPANY OVERVIEW
- 13.3.2 FINANCIAL OVERVIEW
- 13.3.3 PRODUCTS OFFERED
- 13.3.4 KEY DEVELOPMENTS
- 13.3.5 KEY STRATEGIES
13.4 AUROBINDO PHARMA
- 13.4.1 COMPANY OVERVIEW
- 13.4.2 FINANCIAL OVERVIEW
- 13.4.3 PRODUCTS OFFERED
- 13.4.4 KEY DEVELOPMENTS
- 13.4.5 KEY STRATEGIES
13.5 ASPEN HOLDINGS
- 13.5.1 COMPANY OVERVIEW
- 13.5.2 FINANCIAL OVERVIEW
- 13.5.3 PRODUCTS OFFERED
- 13.5.4 KEY DEVELOPMENTS
- 13.5.5 KEY STRATEGIES
13.6 CIPLA LTD
- 13.6.1 COMPANY OVERVIEW
- 13.6.2 FINANCIAL OVERVIEW
- 13.6.3 PRODUCTS OFFERED
- 13.6.4 KEY DEVELOPMENTS
- 13.6.5 SWOT ANALYSIS
- 13.6.6 KEY STRATEGIES
13.7 NOVARTIS AG
- 13.7.1 COMPANY OVERVIEW
- 13.7.2 FINANCIAL OVERVIEW
- 13.7.3 PRODUCTS OFFERED
- 13.7.4 KEY DEVELOPMENTS
- 13.7.5 SWOT ANALYSIS
- 13.7.6 KEY STRATEGIES
13.8 TEVA PHARMACEUTICAL INDUSTRIES LTD
- 13.8.1 COMPANY OVERVIEW
- 13.8.2 FINANCIAL OVERVIEW
- 13.8.3 PRODUCTS OFFERED
- 13.8.4 KEY DEVELOPMENTS
- 13.8.5 SWOT ANALYSIS
- 13.8.6 KEY STRATEGIES
13.9 FRESENIUS SE & CO. KGAA
- 13.9.1 COMPANY OVERVIEW
- 13.9.2 FINANCIAL OVERVIEW
- 13.9.3 PRODUCTS OFFERED
- 13.9.4 KEY DEVELOPMENTS
- 13.9.5 KEY STRATEGIES
13.10 VIATRIS INC.
- 13.10.1 COMPANY OVERVIEW
- 13.10.2 FINANCIAL OVERVIEW
- 13.10.3 PRODUCTS OFFERED
- 13.10.4 KEY DEVELOPMENTS
- 13.10.5 KEY STRATEGIES